Axsome Therapeutics price target raised to $193 from $190 at RBC Capital

RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $193 from $190 and keeps an Outperform rating on the shares. The firm’s survey of 35 neurologists treating Alzheimer’s disease to better understand the enthusiasm for the company’s AXS-05 indicated that two-thirds of surveyed docs were excited by the drug’s profile, and in total, physicians could see 55% of their agitation patients taking AXS-05, the analyst tells investors in a research note. RBC is positive on Axsome as a revenue generating biotech which can insulate it from some of the tariff, intellectual property, and pricing pressures in the sector, the firm adds.